Tl and BMIPP uptake in the area of noncompaction observed before carvedilol disappeared after treatment. Impaired sympathetic neuronal function shown by MIBG recovered after treatment. Thus carvedilol had beneficial eVects on left ventricular function, hypertrophy, and both metabolic and adrenergic abnormalities in isolated left ventricular non-compaction. (Heart 2001;86:e4) 
Isolated left ventricular non-compaction is a rare disorder characterised by prominent trabeculations and deep intertrabecular recesses. 1 The pathogenesis of this disorder is believed to be an arrest in endomyocardial morphogenesis.
1 Prognosis is apparently grim, with a high mortality and morbidity from heart failure, ventricular arrhythmia, and systemic embolisation. 1 2 Despite an increasing awareness of and interest in this disorder, there is still no information about the eVects of medical treatment. This is the first report showing beneficial eVects of carvedilol, a non-selective blocker, on global and regional left ventricular function, left ventricular mass, and scintigraphic findings in a patient with isolated left ventricular non-compaction.
Case report
A four month male infant was admitted to our institution for evaluation of congestive heart failure. He presented with a gallop rhythm and an enlarged heart on chest x ray, with a cardiothoracic ratio of 0.68. His ECG showed ST-T segment depression and an inverted T wave in the left precordial leads from V4-V7, without an abnormal Q wave. On cross sectional echocardiography there was an enlarged left atrium and ventricle and a poorly contracting left ventricle with a fractional shortening of 0.12. Characteristic echocardiographic features compatible with noncompacted myocardium 1 were observed in apical, anterior, lateral, and inferior segments of the left ventricle but not the basal myocardium (fig 1) .
Drug treatment was started initially with diuretics, digitalis, and an angiotensin converting enzyme inhibitor. Carvedilol was added subsequently, initially at a dose of 0.05 mg/kg/ day orally. The dose was increased by 0.05 mg/ kg/day every week until it reached 0.2 mg/kg/ day, and then by 0.2 mg/kg/day at monthly intervals up to 0.8 mg/kg/day. Fixed dose maintenance was continued for a further 14 months. There were no signs and symptoms of worsening heart failure, hypotension, or other adverse eVects related to carvedilol during this period.
Cardiac We also performed magnetic resonance imaging before and after carvedilol (fig 1) , and measured left ventricular mass and per cent wall thickening (table 1) . Left ventricular mass decreased to about two thirds of the baseline value after treatment. Per cent wall thickening increased after carvedilol treatment in the segments corresponding to non-compacted myocardium.
Nuclear studies were performed using single photon emission computed tomography with 201 Tl, 123 I--methyliodophenyl pentadecanoic acid (BMIPP), and 123 I-metaiodobenzylguanidine (MIBG) (fig 1) . Before carvedilol, there was a mismatch between 201 Tl and BMIPP uptake, indicating preserved myocardial viability but compromised oxidative fatty acid metabolism 3 in the areas of noncompaction. Sympathetic nerve dysfunction in non-compacted areas was documented using MIBG-a radiolabelled noradrenaline (norepinephrine) analogue taken up by the sympathetic neuronal terminals-before carvedilol treatment (fig 1) . Nearly normal uptake 15 minutes after the injection of MIBG (MIBG early) and an obviously decreased uptake four hours later (MIBG delayed) indicated preserved cardiac innervation but impaired neuronal function (reduced ability to store MIBG in presynaptic vesicles 4 5 ). After carvedilol treatment there was no longer a mismatch between 201 Tl and BMIPP, and recovery of neuronal function was demonstrated on MIBG delayed images.
Discussion
The main finding in this report was that carvedilol caused a major improvement in isolated left ventricular non-compaction, with beneficial eVects on left ventricular function, mass, and scintigraphic findings. The mechanism of these eVects is not yet clear because the cause of myocardial failure associated with ventricular non-compaction is not understood. A previous report indicated that hypertrophic non-compacted segments are perfused from epicardial coronary arteries, which have no continuity with deep vascular communications with the left ventricular cavity. 1 Microscopic necroses in the subendocardial area and within trabeculations have been documented in histological specimens, and these may be a result of ischaemia. 2 6 Indeed it has been suggested that the myocardial failure and ventricular remodelling that occur in isolated left ventricular noncompaction are caused by ischaemia. 2 Our finding of impaired aerobic fatty acid metabolism in non-compacted segments supports this possible pathogenesis.
US, ultrasound. (A) bottom: short axial mid-ventricular images of cine magnetic resonance imaging at end diastole (ED) and end systole (ES) before (left half) and after (right half) carvedilol treatment. Wall motion and myocardial thickening improved after treatment. (B) Short axial mid-ventricular images of single photon emission computed tomography with MIBG, Tl, and BMIPP before (left half) and after (right half) carvedilol treatment. Top half: before treatment, the MIBG image 15 minutes after injection (early) shows nearly normal uptake, while four hours later (delayed) anterior, lateral, and inferior walls show apparently decreased uptake, indicating preserved sympathetic innervation but impaired intravesicular retention of MIBG; after treatment, the abnormally accelerated washout of MIBG disappeared. Bottom half: before carvedilol treatment the BMIPP image shows relatively decreased uptake at anterior, lateral, and inferior walls compared with myocardial perfusion on the Tl image; after treatment, the mismatch between Tl and BMIPP findings disappeared. BMIPP, -methyliodophenyl pentadecanoic acid; MIBG, metaiodobenzylguanidine.
Carvedilol reversed ventricular dilatation and hypertrophy in our patient. This eVect of carvedilol in reversing remodelling has been widely recognised in myocardial infarction 7 and idiopathic dilated cardiomyopathy. 8 Interestingly, the reversal of remodelling seemed to occur preferentially in non-compacted rather than in compacted myocardium in the present study.
Another significant finding in our study relates to myocardial sympathetic dysfunction and its changes before and after carvedilol treatment. Sympathetic dysfunction has been observed in the myocardium under experimental remodelling. 9 Carvedilol has an eVect of reducing the abnormal release of noradrenaline from remodelling myocardium, 8 and this may lead to myocardial contractile recovery, as shown in the present case. Of note, sympathetic dysfunction in viable myocardium has been recognised as a substrate for ventricular tachycardia, 10 which is often associated with isolated left ventricular non-compaction. 2 
CONCLUSIONS
Carvedilol improved left ventricular function, hypertrophy, and both metabolic and adrenergic abnormalities in isolated left ventricular non-compaction, and this may result in an improved prognosis. 
